SDGR

Schrödinger, Inc.

$32.41

-2.94%
SectorHealthcareIndustryHealth Information ServicesCountryUnited States

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Source: Yahoo Finance
AI summary

Price & performance

1M-11.7%
3M+75.4%
YTD+60.0%
1Y+45.5%
52-week range—
Beta1.67
Full chart and returns against a benchmark

Q-Score

51/ 100

Quality against peers; 50 is the peer median.

Growth56
Risk54
Performance56
Valuation40
Profitability44
Leverage69
Sentiment55
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$255.9M+23.3%
Net income-$103.3M
Net margin-40.4%+49.8 pts
Historical fundamentals

Revenue exposure

40%of revenue from outside the US
United States60%
EMEA29%
APAC10%
Largest customer17%
Regions, segments, customers and suppliers

Valuation

SDGRIndustryP/E—67.40P/S9.014.25EV/EBITDA—44.97P/B8.036.14PEG—0.25
Dividend yield0.00%
Every valuation metric

Earnings

Nov 4next report
EPS estimate—
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate